Opus Genetics, Inc. (IRD) Stock

About Opus Genetics, Inc.

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.

Opus Genetics, Inc. is led by CEO George Magrath, employs 18 people, headquartered in US, publicly traded since 2015.

Opus Genetics, Inc. (IRD) stock trades at $3.32 with a market capitalization of $273.71M. The stock is valued at a price-to-earnings (P/E) ratio of -2.35, price-to-book of -58.39, price-to-sales of 21.22. Over the past 52 weeks the stock has ranged between $1.04 and $5.81, and currently trades 42.9% below its 52-week high.

On profitability, Opus Genetics, Inc. generates a return on equity (ROE) of -333.33%, return on capital employed of -74.91%, an operating margin of -278.57%, a net profit margin of -892.36%.

Official website: opusgtx.com